CHICAGO--(BUSINESS WIRE)--Illinois Cancer Specialists (ICS), an affiliate of The US Oncology Network (The Network), announced today that Progressive Care has joined its practice. The combined practice will continue to offer comprehensive, state-of-the-art cancer care in its nine convenient, patient-friendly community settings throughout suburban Chicago. ICS has been a part of The US Oncology Network, one of the nation’s largest networks of integrated community-based oncology practices, for several years.
“The Network will benefit greatly from the addition of these experienced oncology care providers,” said Marcus Neubauer, M.D., chief medical officer. “I am looking forward to collaborating with them as part of our larger organization in the Chicago area.”
“We’re honored to welcome the physicians and staff from Progressive Care to our practice,” said David Hakimian, M.D., ICS practice president. “This integration brings Chicagoland patients access to 22 physicians in nine of their local communities, giving them confidence that they’re getting the expertise, resources and teamwork they want and need when facing cancer.”
Clinical teams will be integrated to leverage expertise and tools that drive value-based care, and employ the latest technologies and drug therapies to ensure that patients receive high-quality care in a convenient setting. ICS treatment centers feature outpatient treatment and diagnostic facilities including chemotherapy, radiation therapy, positron emission tomography, computerized tomography, stem-cell transplant, clinical research, laboratory, x-ray studies and specialty pharmaceuticals.
“The physicians of Progressive Care have been dedicated to bringing the latest innovations to cancer care for more than 26 years,” said Mark Karides, M.D., Progressive Care practice president. “By coming together with ICS, we are able to advance cancer care even further while maintaining our focus on the compassionate, personalized patient care for which we are known throughout our community.”
By joining ICS, Progressive Care physicians can also collaborate with an expanded physician community of more than 1,400 oncologists in The US Oncology Network. As members of The Network, providers share expertise and best practices through committees, workshops, conferences and via The Oncology Portal, a secure online portal where physicians can share data and collaborate on complex cases. Progressive Care physicians will also be able to utilize Value Pathways, the evidence-based treatment guidelines developed by physicians and clinicians in The Network together with the National Comprehensive Cancer Network® (NCCN®) and other tools and technologies.
About Illinois Cancer Specialists
Illinois Cancer Specialists is dedicated to providing convenient, compassionate and leading-edge cancer care to patients in Chicago and the surrounding areas. With more than 20 physicians and nine locations, ICS brings patients advanced cancer care, along with the tools, resources and support they need to help them through their cancer journey. ICS is proud to offer more: more physician collaboration, more clinical trials and more convenient locations. Find out how patients are a priority at Illinois Cancer Specialists, by visiting www.IllinoisCancerSpecialists.com.
Illinois Cancer Specialists is an affiliate of The US Oncology Network. This collaboration unites ICS with more than 1,400 independent physicians dedicated to delivering value-based, integrated care for patients — close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The US Oncology Network is supported by McKesson Specialty Health, whose coordinated resources and infrastructure allow doctors in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices. ICS also participates in clinical trials through US Oncology Research, which has played a role in more than 70 FDA-approved cancer therapies, approximately one-third of all cancer therapies approved by the FDA to date. For more information, visit www.usoncology.com.